Literature DB >> 19269122

Validation of a liquid chromatography-tandem mass spectrometric assay for the quantitative determination of hydrastine and berberine in human serum.

Prem K Gupta1, Martha Hubbard, Bill Gurley, Howard P Hendrickson.   

Abstract

A high throughput liquid chromatography/tandem mass spectrometry (LC-MS/MS) method for the simultaneous determination of berberine and hydrastine in human serum, after oral administration of goldenseal (Hydrastis canadensis L.), was developed using simple acetonitrile treatment of serum samples. Noscapine served as the internal standard. Lower limit of quantification for both analytes was 0.1 ng mL(-1) using positive ion electrospray tandem mass spectrometry (MS/MS). The intra-day (n=5) accuracy and precision of the method for hydrastine was 82+/-8.8%, 97.9+/-2.4% and 96.2+/-3.3%, respectively. The inter-day (n=4) accuracy and precision for hydrastine was 90.0+/-15.17%, 99.9+/-7.1% and 98+/-6.54%, respectively. For berberine quantitation intra-day accuracy and precision was 96.0+/-8.4%, 92.5+/-4.7% and 94.4+/-3.7%, respectively. The respective values for inter-day quantitation were 91.0+/-8.4%, 94.3+/-4.7% and 94.4+/-3.7%. The analytical recovery for hydrastine was 82.4-96.2% and for berberine it was 94.4-96.0%. The analytes and noscapine were stable for 24h at room temperature (CV 5-10%). Matrix ion effects were studied by post-column infusion of hydrastine and berberine, calculation of calibration curve slope precision was obtained using serum from five different subjects, and by comparison of the response of methanol standards and extracted serum samples. The method was further validated by determination of serum pharmacokinetics of hydrastine and berberine after administration of a single oral dose of goldenseal extract containing 77 mg of hydrastine and 132 mg of berberine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19269122     DOI: 10.1016/j.jpba.2009.01.036

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  7 in total

1.  Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats.

Authors:  Wei Chen; Yu-Qiang Miao; Dong-Jiao Fan; Shen-Shen Yang; Xia Lin; Ling-Kuo Meng; Xing Tang
Journal:  AAPS PharmSciTech       Date:  2011-06-03       Impact factor: 3.246

2.  Modulation of Major Human Liver Microsomal Cytochromes P450 by Component Alkaloids of Goldenseal: Time-Dependent Inhibition and Allosteric Effects.

Authors:  Matthew G McDonald; Dan-Dan Tian; Kenneth E Thummel; Mary F Paine; Allan E Rettie
Journal:  Drug Metab Dispos       Date:  2020-06-26       Impact factor: 3.922

3.  Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib.

Authors:  Jeffry Adiwidjaja; Alan V Boddy; Andrew J McLachlan
Journal:  Eur J Clin Pharmacol       Date:  2022-01-20       Impact factor: 2.953

4.  Approaches to improve the oral bioavailability and effects of novel anticancer drugs berberine and betulinic acid.

Authors:  Chandraiah Godugu; Apurva R Patel; Ravi Doddapaneni; Jaganmohan Somagoni; Mandip Singh
Journal:  PLoS One       Date:  2014-03-10       Impact factor: 3.240

5.  Comparative pharmacokinetics and safety assessment of transdermal berberine and dihydroberberine.

Authors:  Beth Buchanan; Qingfang Meng; Mathieu-Marc Poulin; Jonathan Zuccolo; Chike Godwin Azike; Joseph Gabriele; David Charles Baranowski
Journal:  PLoS One       Date:  2018-03-26       Impact factor: 3.240

Review 6.  Berberine in Human Oncogenic Herpesvirus Infections and Their Linked Cancers.

Authors:  Miroslava Šudomová; Kateřina Berchová-Bímová; Stefania Marzocco; Alena Liskova; Peter Kubatka; Sherif T S Hassan
Journal:  Viruses       Date:  2021-05-28       Impact factor: 5.048

7.  Exploratory Pharmacokinetics of Geniposide in Rat Model of Cerebral Ischemia Orally Administered with or without Baicalin and/or Berberine.

Authors:  Linmei Pan; Wenzhe Wang; Feiyan Shi; Jing Zhou; Meng Zhang; Huaxu Zhu; Mingfei Zeng
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-03       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.